Has John Deans, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,615 in general payments to John Deans, MD across 60 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Deans, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Deans, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Deans, MD

Ophthalmology · Wilmington, NCNPI 1407210057

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.2% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 34.0% of the total.

$2,615in general payments, 2019–2025

Across 60 payments — averaging $43.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson Surgical Vision, Inc.$890
Regeneron Healthcare Solutions, Inc.$315
Bausch & Lomb Americas Inc.$307
Genentech USA, Inc.$228
AbbVie$197
Astellas Pharma US Inc$188
plus $490 from 10 others

$420in research payments, 2019–2025

Across 10 payments — averaging $42.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Notal Vision, Inc.$420

What the payments were for

Speaking & faculty fees$1265%
Food & beverage$2,48895%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson Surgical Vision, Inc.	13	$890
Regeneron Healthcare Solutions, Inc.	8	$315
Bausch & Lomb Americas Inc.	4	$307
Genentech USA, Inc.	6	$228
AbbVie	9	$197
Astellas Pharma US Inc	7	$188
Notal Vision, Inc.	1	$126
Alcon	1	$105
Harrow Eye, LLC	2	$56
Carl Zeiss Meditec Cataract Technology Inc.	1	$46
Glaukos Corporation	2	$43
Alimera Sciences, Inc.	2	$38
ANI Pharmaceuticals, Inc.	1	$21
Apellis Pharmaceuticals, Inc.	1	$20
Topcon Healthcare, Inc.	1	$19
Carl Zeiss Meditec, Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,615 in reported general payments places this provider in the 65th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina →

Medicare billing

Part B allowed, 2024

$4,542,607

Medicare patients

1,257

Services billed

74,400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	184	$7,965
Atropine Sulfate	71	$2,648
MoxifloxacinMoxifloxacin Hcl	114	$2,426
Bromfenac Sodium	14	$1,843
Ketorolac Tromethamine	53	$1,556
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	67	$1,236
Brimonidine Tartrate	30	$859
ValacyclovirValacyclovir Hcl	17	$455
Latanoprost	36	$312
Timolol Maleate	30	$273
Prednisone	17	$92

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Wilmington

Robert van der VaartWilmington$50K
Matej PolomskyWilmington$20K
Samantha WatsonWilmington$11K
Clark SpringsWilmington$10K
Alan BrownWilmington$10K
Preeya GuptaRaleigh$1.8M
Julie WoodwardDurham$1M
Rajiv ShahWinston Salem$909K
Lejla VajzovicDurham$681K
Karl StonecipherGreensboro$653K

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →